Bionano Genomics, Inc. (NASDAQ:BNGO) Stock Short Interest Rises 77.9%

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 2,035,020 shares, an increase of 77.9% from the September 15th total of 1,144,194 shares. Based on an average daily volume of 978,648 shares, the days-to-cover ratio is currently 2.1 days. Currently, 17.4% of the company’s stock are short sold.

Bionano Genomics Trading Down 1.8%

BNGO stock traded down $0.03 during midday trading on Friday, reaching $1.34. The stock had a trading volume of 31,643 shares, compared to its average volume of 462,216. The company has a quick ratio of 1.96, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. The firm has a market cap of $15.84 million, a price-to-earnings ratio of -0.45 and a beta of 1.66. The business has a fifty day simple moving average of $1.37 and a two-hundred day simple moving average of $1.25. Bionano Genomics has a twelve month low of $1.00 and a twelve month high of $2.23.

Bionano Genomics (NASDAQ:BNGO) last issued its earnings results on Monday, August 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. The firm had revenue of ($6.67) million for the quarter, compared to analysts’ expectations of $7.55 million. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%. As a group, research analysts expect that Bionano Genomics will post -2.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BNGO shares. Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Wall Street Zen upgraded Bionano Genomics to a “hold” rating in a research note on Saturday, September 26th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Bionano Genomics has an average rating of “Hold” and an average price target of $6.00.

Institutional Trading of Bionano Genomics

A hedge fund recently bought a new position in Bionano Genomics stock. GSA Capital Partners LLP purchased a new stake in Bionano Genomics, Inc. (NASDAQ:BNGO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 150,284 shares of the company’s stock, valued at approximately $170,000. GSA Capital Partners LLP owned 1.31% of Bionano Genomics at the end of the most recent reporting period. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc is a life sciences company that develops genomic analysis solutions based on optical genome mapping (OGM). Its technology is designed to identify structural variations and other genomic abnormalities that may be difficult to detect with traditional sequencing and cytogenetic methods.

The company’s principal platform is the Saphyr system, which includes instrumentation, consumables and software for analyzing ultra-long DNA molecules. Bionano also provides data-analysis tools and informatics solutions intended to support research and clinical workflows in areas such as constitutional genetics, oncology and hematologic malignancies.

Bionano Genomics serves academic, government, pharmaceutical and biotechnology researchers, as well as clinical laboratories in the United States and international markets.